SERA PROGNOSTICS, INC. Total Liabilities and Equity
SERA PROGNOSTICS, INC. (SERA) had Total Liabilities and Equity of $86.74 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-12
- 2026-06-30: Liabilities and Equity $86.74M.
- 2026-03-31: Liabilities and Equity $93.54M.
- 2025-12-31: Liabilities and Equity $101.93M.
- 2025-09-30: Liabilities and Equity $108.13M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $86.74M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $93.54M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $101.93M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $108.13M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $111.83M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $118.18M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $72.58M 10-K · filed 2026-03-18 |
| 2024-09-30 | $79.00M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $84.86M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $89.89M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $95.44M 10-K · filed 2025-03-19 |
| 2023-09-30 | $90.06M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $96.68M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $105.61M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $116.33M 10-K · filed 2024-03-20 |
| 2022-09-30 | $116.56M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $125.06M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $134.87M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $147.03M 10-K · filed 2023-03-22 |
| 2021-09-30 | $153.69M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $95.07M 10-Q · filed 2021-08-30 |
| 2020-12-31 | $14.80M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |